Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$113.14
+1.7%
$116.69
$73.31
$125.14
$279.33B0.1811.03 million shs3.23 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$53.81
+1.8%
$51.79
$22.28
$59.55
$21.35B1.059.84 million shs6.03 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$53.71
-0.5%
$58.09
$28.64
$65.00
$7.76B1.31.39 million shs741,513 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.99
+0.7%
$27.09
$21.97
$28.75
$148.10B0.3542.63 million shs16.64 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$40.75
+3.7%
$27.67
$6.74
$41.88
$673.07M1.63184,524 shs125,413 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.20%-0.73%-8.18%-4.82%+46.91%
Moderna, Inc. stock logo
MRNA
Moderna
-2.70%+16.55%+3.77%+25.93%+118.06%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.85%-5.16%-11.32%-1.80%+73.27%
Pfizer Inc. stock logo
PFE
Pfizer
+0.67%-1.99%-4.03%-6.48%+15.89%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-2.31%+10.45%+52.01%+151.34%+351.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$113.14
+1.7%
$116.69
$73.31
$125.14
$279.33B0.1811.03 million shs3.23 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$53.81
+1.8%
$51.79
$22.28
$59.55
$21.35B1.059.84 million shs6.03 million shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$53.71
-0.5%
$58.09
$28.64
$65.00
$7.76B1.31.39 million shs741,513 shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.99
+0.7%
$27.09
$21.97
$28.75
$148.10B0.3542.63 million shs16.64 million shs
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$40.75
+3.7%
$27.67
$6.74
$41.88
$673.07M1.63184,524 shs125,413 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+0.20%-0.73%-8.18%-4.82%+46.91%
Moderna, Inc. stock logo
MRNA
Moderna
-2.70%+16.55%+3.77%+25.93%+118.06%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.85%-5.16%-11.32%-1.80%+73.27%
Pfizer Inc. stock logo
PFE
Pfizer
+0.67%-1.99%-4.03%-6.48%+15.89%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-2.31%+10.45%+52.01%+151.34%+351.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.1813.29% Upside
Moderna, Inc. stock logo
MRNA
Moderna
1.84
Reduce$35.73-33.59% Downside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.63
Moderate Buy$86.0060.13% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.23
Hold$28.7410.59% Upside
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
2.85
Moderate Buy$40.780.07% Upside

Current Analyst Ratings Breakdown

Latest PCVX, PFE, MRNA, STRO, and MRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
Reiterated RatingSell (D-)
5/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C-)Hold (C)
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$36.00 ➝ $45.00
5/4/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$35.00 ➝ $38.00
5/4/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
UpgradeStrong-Buy
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetNeutral$43.00 ➝ $49.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$33.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetOverweight$150.00 ➝ $145.00
5/1/2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
UpgradeStrong-Buy
(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.30$11.60 per share9.75$21.22 per share5.33
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B10.98N/AN/A$22.14 per share2.43
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$20.51 per shareN/A
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.37$4.45 per share5.84$15.26 per share1.70
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
$102.48M6.59N/AN/A($15.43) per share-2.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5531.8611.582.5113.59%27.55%10.73%N/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$766.63M-$6.88N/AN/AN/AN/A-32.51%-29.51%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$1.3119.849.09N/A11.83%19.44%8.41%N/A
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$191.09M-$26.10N/AN/AN/A-186.45%N/A-79.02%5/14/2026 (Estimated)

Latest PCVX, PFE, MRNA, STRO, and MRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
-$2.7363N/AN/AN/A$8.89 millionN/A
5/6/2026Q1 2026
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.7411-$2.30-$0.5589-$2.30$12.50 millionN/A
5/5/2026Q1 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7220$0.75+$0.0280$0.47$13.84 billion$14.45 billion
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
2/24/2026Q4 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A
2/13/2026Q4 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.79-$2.11+$0.68-$2.11$611.14 million$678.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.403.01%+5.75%95.77%14 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.62%-13.20%131.30%16 Years
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/AN/AN/AN/AN/A

Latest PCVX, PFE, MRNA, STRO, and MRK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.436.71%5/8/20265/8/20266/12/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
7.49
7.49
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.25
0.94
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
N/A
2.01
2.01

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
96.99%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
5.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160144.40 million139.92 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable
Sutro Biopharma, Inc. stock logo
STRO
Sutro Biopharma
24016.57 million15.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$113.14 +1.86 (+1.67%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Moderna stock logo

Moderna NASDAQ:MRNA

$53.81 +0.93 (+1.75%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$53.70 -0.29 (-0.53%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Pfizer stock logo

Pfizer NYSE:PFE

$25.98 +0.18 (+0.68%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sutro Biopharma stock logo

Sutro Biopharma NASDAQ:STRO

$40.75 +1.44 (+3.67%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.